Neha Vagadia, DO
Critical Care Medicine · Marlton, NJNPI 1649326463
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,700 of the $31,392 with a category attached, or 78.7%. GSK accounts for 92.5% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $29,605, more than ten times the $128 reported in 2019. Among critical care medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $159.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$29K
- AstraZeneca$775
- Harmony Biosciences LLC$358
- Regeneron Healthcare Solutions, Inc.$312
- Amgen$141
- Sanofi$133
- plus $629 from 15 others
What the payments were for
- Speaking & faculty fees$24,70079%
- Travel & lodging$2,2657%
- Food & beverage$4,16213%
- Education$2651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $29,045 |
| AstraZeneca | 20 | $775 |
| Harmony Biosciences LLC | 12 | $358 |
| Regeneron Healthcare Solutions, Inc. | 9 | $312 |
| Amgen | 9 | $141 |
| Sanofi | 7 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| Vapotherm Inc | 1 | $85 |
| Inspire Medical Systems, Inc. | 3 | $70 |
| Verona Pharma, Inc. | 4 | $70 |
| ANI Pharmaceuticals, Inc. | 3 | $56 |
| Insmed, Inc. | 3 | $56 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Philips North America LLC | 1 | $27 |
| Resmed Corp | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,392 in reported general payments places this provider in the 95th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 275 | $246,042 |
| Fasenra PenBenralizumab | 19 | $110,410 |
| Breo ElliptaFluticasone/Vilanterol | 131 | $69,302 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 112 | $64,354 |
| Spiriva HandihalerTiotropium Bromide | 41 | $40,026 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $29,564 |
| EliquisApixaban | 39 | $26,989 |
| Spiriva RespimatTiotropium Bromide | 35 | $22,481 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 96 | $16,734 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $12,922 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $10,114 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $9,294 |
| Arnuity ElliptaFluticasone Furoate | 22 | $8,382 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 253 | $7,805 |
| Tiotropium Bromide | 14 | $7,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $29,045 | $394,057554 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $17 | $32,59647 claims |
| AstraZenecaBreztri Aerosphere | $775 | $29,56444 claims |
| PfizerEliquis | $13 | $26,98939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Marlton
- Syed RiazMarlton$12K
- Aaron CrookshankMarlton$8K
- Emilio MazzaMarlton$7K
- Eric SztejmanMarlton$6K
- Jonathan GalliMarlton$5K
- Rohit MalikMarlton$5K
- Angel RodisMarlton$4K
- Andrew SchiffMarlton$4K
- Roman KrolMarlton$4K
- Brian JaffeMarlton$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.